Table 24Characteristics of liraglutide active-control trials in adults with type 2 diabetes

Author, year
Country
Quality
Sample size (N)
Follow-up (weeks)
Age (years) (SD)a
% Malea
% Whitea
% Hispanica
Diabetes duration (years)a
Baseline HbA1c (%) (SD)a
Weight (kg)a
BMI (kg/m2)a
InterventionCombination therapy
Madsbadb 200458
Scandinavia and UK
Fair
193
12
53–58 (7.5–11.3)
57–85
NR
NR
3.4–6.1 (2.9–7.9)
7.4–7.9 (0.8–1.2)
NR
30.1–32.0 (4.2–5.4)
LIR 0.045 mg, 0.225 mg, 0.45 mg, 0.60 mg, or 0.75 mg daily
Placebo
Glimepiride 1–4 mg
None
Garber, 200960
Bode, 201085
US and Mexico
Fair
746
52
52–53.7 (10.8–11.0)
47–54
75–80
32–38
5.2–5.6 (5.1–5.5)
8.3–8.3 (1–1.2)
92.5–93.4 (19.2–20.7)
32.8–33.2 (5.6–6.3)
LIR 1.2 mg daily
LIR 1.8 mg daily
Glimepiride 8 mg daily
None
Nauckb 200959
Multinational
Fair
1091
26
56–57 (9–11)
54–62
84–89
NR
7–8 (5–6)
8.3–8.4 (0.9–1.1)
NR
30.5–31.6 (4.4–4.8)
LIR 0.6 mg daily
LIR 1.2 mg daily
LIR 1.8 mg daily
Placebo
Glimepiride 4 mg daily
All groups received metformin 1 g BID
Russell-Jonesb 200983
Multinational
Good
581
26
57.5–57.6 (9.5–10.5)
49–60
NR
NR
9.2–9.7 (5.8–6.4)
8.2–8.3 (0.9)
85.0–85.7 (16.7–17.9)
30.3–31.3 (5–5.3)
LIR 1.8 mg daily
Placebo
Insulin glargine
All groups received metformin 1 g BID and glimepiride 4 mg daily
Marreb 200984
Multinational
Fair
1041
26
54.7–57.7 (9.0–10.0)
45–54
NR
NR
6.5–6.7 (NR)
8.4–8.5 (0.9–1.1)
80.0–83.0 (17.0–18.1)
29.4–30.3 (4.8–5.4)
LIR 0.6 mg daily
LIR 1.2 mg daily
LIR 1.8 mg daily
Placebo
Rosiglitazone 4 mg
All groups on glimepiride 2–4 mg daily
Pratley 201041
Multinational
Fair
665
26
55.0–55.9 (9.0–9.6)
52–55
82–91
15–16
6.0–6.4 (4.5–5.4)
8.4–8.5 (0.7–0.8)
93.1–94.6 (18.1–18.9)
32.6–33.1 (5.1–5.4)
LIR 1.2 mg daily
LIR 1.8 mg daily
Sitagliptin 100 mg
All groups on metformin ≥ 1500 mg daily

Abbreviations: BID, twice daily; BMI, body mass index; LIR, liraglutide; NR, not reported; SD, standard deviation.

a

Data presented are the range across treatment groups for mean and standard deviation.

b

Studies with both placebo and active control arms repeated in Tables 25 and 26.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.